Scarica l'app Stockscreener
2.95
3.91%
-0.12
Dopo l'orario di chiusura:
2.96
0.010
+0.34%
Panoramica
Notizia
Cronologia dei prezzi
Perché EVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$3.07
Aprire:
$2.99
Volume 24 ore:
39,558
Relative Volume:
0.39
Capitalizzazione di mercato:
$1.05B
Reddito:
$890.87M
Utile/perdita netta:
$-115.85M
Rapporto P/E:
-9.0463
EPS:
-0.3261
Flusso di cassa netto:
$-104.29M
1 W Prestazione:
+1.37%
1M Prestazione:
-4.53%
6M Prestazione:
-8.10%
1 anno Prestazione:
-25.88%
Intervallo 1D:
$2.92
$2.99
Intervallo di 1 settimana:
$2.85
$3.08
Portata 52W:
$2.308
$4.44
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
2.95 | 1.09B | 890.87M | -115.85M | -104.29M | -0.3261 |
TAK
Takeda Pharmaceutical Co Adr
|
15.18 | 48.00B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.08 | 40.34B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.70 | 39.10B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
76.39 | 32.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
540.05 | 23.12B | 3.17B | 1.29B | 1.01B | 27.09 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Ripresa | H.C. Wainwright | Buy |
| 2026-02-03 | Iniziato | Berenberg | Buy |
| 2025-04-24 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-10-07 | Downgrade | Jefferies | Buy → Hold |
| 2024-08-08 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-07-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-04-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-04-04 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | Iniziato | H.C. Wainwright | Buy |
| 2022-11-16 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-08-10 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2022-01-07 | Ripresa | Citigroup | Neutral |
Mostra tutto
Evotec Se Adr Borsa (EVO) Ultime notizie
Evotec SE stock (DE0005664809): After CEO exit and audit delay, investors watch turnaround plans - AD HOC NEWS
Evotec ADR Slides 4.3% as Selling Pressure Tests Key Support LevelsQuality Factor - thelegaladvocate.com
Evotec SE stock (DE0005664809): Steady FY 2025 results amid US expansion - AD HOC NEWS
Evotec AG Earnings Call Balances Pain With Promise - The Globe and Mail
Evotec SE stock (DE0005664809): Drug discovery leader eyes US biotech growth - AD HOC NEWS
Evotec places €116.1 million convertible bonds due 2033 - Investing.com UK
Evotec places €116.1 million convertible bonds due 2033 By Investing.com - Investing.com South Africa
Evotec SE stock (DE0005664809): Recent price gains signal short-term momentum - AD HOC NEWS
Evotec SE stock (DE0005664809): HC Wainwright cuts Q2 earnings outlook - AD HOC NEWS
Boyd Gaming posts downbeat Q1 results, joins Coursera, Evotec and other big stocks moving lower in Friday's pre-market session - MSN
Evotec SE stock (DE0005664809): Q1 2026 results show sharp revenue drop amid restructuring - AD HOC NEWS
Earnings call transcript: Evotec Q1 2026 sees revenue drop amid market challenges - Investing.com Canada
Evotec Q1 2026 slides: revenue drops 22% as transformation accelerates By Investing.com - Investing.com Nigeria
Evotec Q1 2026 slides: revenue drops 22% as transformation accelerates - Investing.com
Earnings call transcript: Evotec Q1 2026 sees revenue drop amid market challenges By Investing.com - Investing.com South Africa
Evotec reports wider quarterly loss, misses revenue expectations By Investing.com - Investing.com Canada
Evotec reports wider quarterly loss, misses revenue expectations - Investing.com
Evotec's Share Price Surges! Summer Rally for Desert Gold? Rheinmetall Shares Heading Toward EUR 2,000? - news.financial
Evotec SE Stock (DE0005664809): Q1 2026 Results Due Today - AD HOC NEWS
Evotec nominates Wolfgang Hofmann to supervisory board By Investing.com - Investing.com Australia
Evotec nominates Wolfgang Hofmann to supervisory board - Investing.com
Boyd Gaming Posts Downbeat Q1 Results, Joins Coursera, Evotec And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
Evotec names Claire Hinshelwood as CFO, replacing Paul Hitchin By Investing.com - Investing.com Australia
Boyd Gaming Posts Downbeat Q1 Results, Joins Coursera, Evotec And Other Big Stocks Moving Lower In Friday - Benzinga
Evotec names Claire Hinshelwood as CFO, replacing Paul Hitchin - Investing.com
Middle East Conflict Weighs on Markets: Food Supply Chains Become a Key Issue – MustGrow, K+S, Evotec, and BioNTech in the Spotlight - news.financial
Evotec SE stock (DE0005664809): Is its drug discovery platform strong enough for biotech recovery? - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery pipeline strong enough to unlock biotech upsid - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery platform strong enough to unlock biotech upsid - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery partnership model strong enough for steady ups - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery partnership model strong enough for biotech re - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery model strong enough to unlock biotech upside? - AD HOC NEWS
Evotec appoints Ingrid Müller as chief operating officer - Investing.com
Evotec SE stock (DE0005664809): Is its drug discovery model strong enough to unlock new upside? - AD HOC NEWS
100% Profit Potential in Sight: Vidac Pharma's Chance to Double vs Bayer and Evotec - news.financial
Evotec Se Adr Azioni (EVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.73%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):